Bet v 1-specific Immunoglobulin E and Immunoglobulin G (Bet v 1-specific IgE/IgG)

Bet v 1-specific Immunoglobulin E (IgE) and Immunoglobulin G (IgG) are the primary immunological mediators involved in the pathogenesis and clinical management of birch pollen allergy. Bet v 1 is the major allergen of birch (Betula verrucosa) pollen, and in sensitized individuals, Bet v 1-specific IgE binds to the allergen, triggering the cross-linking of high-affinity IgE receptors (FcεRI) on mast cells and basophils (WHO/IUIS Allergen Nomenclature). This process leads to the immediate release of histamine and other inflammatory mediators, resulting in clinical symptoms such as allergic rhinitis, conjunctivitis, and asthma. Therapeutic interventions, specifically allergen immunotherapy (AIT), aim to modulate this response by inducing the production of Bet v 1-specific IgG antibodies, particularly the IgG4 subclass (Shamji MH & Durham SR, 2011). These IgG4 antibodies function as blocking antibodies that intercept the allergen before it can bind to cell-bound IgE, thereby inhibiting the allergic cascade and promoting long-term immune tolerance. Monitoring the levels and ratios of these antibodies serves as a critical biomarker for assessing patient sensitization, predicting clinical severity, and evaluating the efficacy of immunotherapy treatments (Valenta R, et al., 2010). Additionally, monoclonal antibodies like Omalizumab can be used to neutralize the IgE component directly, further illustrating the target's central role in allergic disease.

Other names

Anti-Bet v 1 antibodiesBirch pollen-specific antibodiesBet v 1-reactive IgE and IgGBirch allergen-specific immunoglobulins

Allergen immunotherapy (AIT) works by inducing the production of allergen-specific IgG4 antibodies that act as blocking antibodies, competing with IgE for allergen binding and preventing the cross-linking of FcεRI receptors on mast cells and basophils (Shamji MH, et al., 2011).